Literature DB >> 7583051

Effects of antihypertensive therapy on blood pressure and renal function in rats with hypertension due to chronic blockade of nitric oxide synthesis.

C M Erley1, S Rebmann, U Strobel, T Schmidt, M Wehrmann, H Osswald, T Risler.   

Abstract

Different antihypertensive treatment regimes were studied in rats during long-term inhibition of nitric oxide synthesis. Male Munich Wistar rats (weight 150-200 g) were put on oral L-nitro-arginine methyl ester (L-NAME, 50 mg/l drinking water) for 12 weeks. The control group (n = 16) received only tap water. Six weeks after starting L-NAME administration rats were divided into 7 groups (n = 13 in each group: group 1, no treatment; group 2, l-arginine 1 g/l drinking water; group 3, doxazosin 30 mg/kg/day; group 4, felodipine 25-30 mg/kg/day; group 5, losartan 40 mg/kg/day; group 6, metoprolol 300-350 mg/kg/day, and group 7, ramipril 1 mg/kg/day. Systolic blood pressure (sBP) was measured in the conscious rat 1, 6, and 12 weeks after study begin. After a treatment period of 6 weeks albuminuria, glomerular filtration rate (GFR) and renal plasma flow (RPF; inulin and p-aminohippuric acid clearance) were analyzed. All rats showed a significant increase in sBP under 6 weeks of L-NAME administration. Control rats remained normotensive during the whole study period. Rats receiving L-NAME without antihypertensive treatment showed a further increase in sBP after 12 weeks. Blood pressure was lowered in all treated animals, except in rats receiving l-arginine. Values for GFR were lowest in the placebo group, the l-arginine group and in rats receiving felodipine (p < 0.05 compared to the control group). RPF was lowest in the placebo group, the l-arginine group, the felodipine group and the ramipril group (p < 0.05 compared to the control group).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7583051

Source DB:  PubMed          Journal:  Exp Nephrol        ISSN: 1018-7782


  6 in total

1.  Role of endothelin-1 in the hyper-responsiveness to nitrovasodilators following acute NOS inhibition.

Authors:  Stephane L Bourque; Heather A Whittingham; Susan E Brien; Sandra T Davidge; Michael A Adams
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 2.  Chronic nitric oxide inhibition model six years on.

Authors:  R Zatz; C Baylis
Journal:  Hypertension       Date:  1998-12       Impact factor: 10.190

3.  End-organ protection in hypertension by the novel and selective Rho-kinase inhibitor, SAR407899.

Authors:  Matthias Löhn; Oliver Plettenburg; Aimo Kannt; Markus Kohlmann; Armin Hofmeister; Dieter Kadereit; Peter Monecke; Alexander Schiffer; Anke Schulte; Hartmut Ruetten; Yuri Ivashchenko
Journal:  World J Cardiol       Date:  2015-01-26

4.  PPAR-gamma agonist rosiglitazone reverses increased cerebral venous hydraulic conductivity during hypertension.

Authors:  Tim J M Roberts; Abbie C Chapman; Marilyn J Cipolla
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-08-07       Impact factor: 4.733

Review 5.  Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics.

Authors:  Emily J Tsai; David A Kass
Journal:  Pharmacol Ther       Date:  2009-03-21       Impact factor: 12.310

Review 6.  Role of α- and β-adrenergic signaling in phenotypic targeting: significance in benign and malignant urologic disease.

Authors:  M Archer; N Dogra; Z Dovey; T Ganta; H-S Jang; J A Khusid; A Lantz; M Mihalopoulos; J A Stockert; A Zahalka; L Björnebo; S Gaglani; M R Noh; S A Kaplan; R Mehrazin; K K Badani; P Wiklund; K Tsao; D J Lundon; N Mohamed; F Lucien; B Padanilam; M Gupta; A K Tewari; N Kyprianou
Journal:  Cell Commun Signal       Date:  2021-07-20       Impact factor: 5.712

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.